SABCS 2022 Conference Coverage


 

SABCS 2022 Phase III SWOG S1207 Trial: Evaluating Adjuvant ET +/- 1 Year of Everolimus in Patients With High-Risk HR+/HER2- BC

62 views
December 14, 2022
Comments 0
Login to view comments. Click here to Login